Evolving role of (18)F-fluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma.
Positron emission tomography (PTE) and PET/CT imaging with (18)F-fluorodeoxyglucose are metabolic imaging modalities that depict tissues based on their level of glucose uptake. PET provides useful information in the primary staging of disease. PET performance in detecting locoregional nodal metastases is limited; however, it is the most accurate single noninvasive modality for detecting distant metastases. It is the imaging modality of choice for whole-body scanning in high-risk patients or patients who have clinically suspected recurrence, and is particularly helpful in determining which patients are the best candidates for surgical cure.
Dam
Hung Q
HQ
Department of Nuclear Medicine, Christiana Care Health System/Helen F. Graham Cancer Center, 4755 Ogletown-Stanton Road, Newark, DE 19718, USA. hdam@christianacare.org
Manzone
Timothy M
TM
Sagar
Vidya V
VV
D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000628:therapy; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000175:diagnosis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18